BetterLife Pharma Income Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Cost of Revenue	-	-	-	-	-	0.02
Gross Profit	-	-	-	-	-	-0.02
Selling, General & Admin	1.94	4.3	2.64	6.56	4.53	7.56
Research & Development	0.06	0.42	0.57	2.68	5.42	0.28
Operating Expenses	2	4.72	3.21	9.26	9.97	7.93
Operating Income	-2	-4.72	-3.21	-9.26	-9.97	-7.95
Interest Expense	-0.11	-0.32	-0.05	-0.07	-0.06	-0.04
Interest & Investment Income	-	-	-	-	-	0
Currency Exchange Gain (Loss)	-0.02	-0.28	-0.03	-0.2	-0.24	0.04
Other Non Operating Income (Expenses)	-0.22	0.73	-0.17	-0	-1.07	-0.3
EBT Excluding Unusual Items	-2.35	-4.59	-3.46	-9.53	-11.33	-8.25
Gain (Loss) on Sale of Assets	-	-	-	-	0.19	-15.86
Asset Writedown	-	-	-	-	-	-12.12
Legal Settlements	-	0.56	0.13	0.26	-0.56	-0.12
Other Unusual Items	0.45	0.42	0.44	-0.1	-0.29	-
Pretax Income	-1.9	-3.62	-2.9	-9.37	-11.99	-36.35
Income Tax Expense	-	-	-	-	0.17	-
Earnings From Continuing Operations	-1.9	-3.62	-2.9	-9.37	-12.16	-36.35
Minority Interest in Earnings	0.05	0.1	0.01	0.36	-	-
Net Income	-1.85	-3.52	-2.89	-9.02	-12.16	-36.35
Net Income to Common	-1.85	-3.52	-2.89	-9.02	-12.16	-36.35
Shares Outstanding (Basic)	140	124	109	87	75	27
Shares Outstanding (Diluted)	140	124	109	87	75	27
Shares Change (YoY)	16.79%	13.34%	26.25%	14.70%	179.24%	79.75%
EPS (Basic)	-0.01	-0.03	-0.03	-0.10	-0.16	-1.34
EPS (Diluted)	-0.02	-0.03	-0.03	-0.10	-0.16	-1.34
Free Cash Flow	-0.22	-2.02	-2.47	-1.5	-11.2	-7.18
Free Cash Flow Per Share	-0.00	-0.02	-0.02	-0.02	-0.15	-0.27
EBITDA	-	-	-3.19	-9.24	-9.95	-7.8
D&A For EBITDA	-	-	0.02	0.02	0.02	0.16
EBIT	-2	-4.72	-3.21	-9.26	-9.97	-7.95
Advertising Expenses	-	-	-	0.12	0.44	0.19

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.